Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 3

2(28.6%)

7Total

Phase 2(5)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04567784Phase 2Completed

Neuroimaging and CBD for Opioid Use Disorder

Role: collaborator

NCT02224573Phase 3Completed

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

Role: lead

NCT02818777Phase 2Completed

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

Role: collaborator

NCT01562314Phase 2Completed

A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)

Role: lead

NCT01284634Phase 2Completed

Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

Role: lead

NCT01868048Phase 3Withdrawn

Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

Role: lead

NCT01491490Phase 2Terminated

Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine

Role: lead

All 7 trials loaded